GlassScriptPhysician profile
Robert K Durnford
NPI 1922095827
$1,565.05
in general payments reported to CMS, 2019-2025
13 companies · $319 in 2025
The $319 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $14.21 · 2021: $15.50 · 2022: $45.15 · 2023: $304 · 2024: $424 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,047.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,046.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $639.18 | 2022-2025 | Rinvoq, Skyrizi, Linzess |
| Pfizer INC. | $188.12 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $148.43 | 2019-2025 | Xifaxan |
| Celgene Corporation | $131.86 | 2023-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $100.88 | 2019-2023 | Entyvio |
| Boston Scientific Corporation | $99.38 | 2019 | |
| Janssen Biotech, INC. | $95.81 | 2019-2024 | Stelara, Tremfya |
| Allergan, INC. | $67.99 | 2019 | |
| Braintree Laboratories, INC. | $23.63 | 2023 | Suflave |
| Ucb, INC. | $21.46 | 2019 | |
| Gilead Sciences, INC. | $17.99 | 2019 | |
| Intercept Pharmaceuticals, INC. | $15.49 | 2024 | |
| Echosens North America, INC. | $14.83 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Durnford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.